Filtered By:
Source: Clinical and Applied Thrombosis/Hemostasis
Condition: Thrombosis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 33 results found since Jan 2013.

Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Atrial fibrillation (AF) is a significant risk factor for stroke and peripheral thromboembolic events (TEs). Preventing blood clots in the heart to reduce stroke and TE risk is a key goal of AF therapy. Traditional stroke risk assessment tools for patients with nonvalvular AF include the CHADS2 and CHA(2)DS(2)-VASc scores, while long-term outcome data with the newer direct oral anticoagulants (DOACs) are emerging. The goals of this review were to assess traditional therapies and existing treatment guidelines and to discuss key pharmacologic properties of the DOACS, noting how these may benefit at-risk patients with AF. Thi...
Source: Clinical and Applied Thrombosis/Hemostasis - November 27, 2016 Category: Hematology Authors: Stacy, Z., Richter, S. Tags: Review Source Type: research

Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes
Anticoagulation therapy is central to the management of thromboembolic disorders, and the use of direct oral anticoagulants offers several advantages over standard therapy with parenteral heparins and vitamin K antagonists. In phase III clinical trials, the direct oral anticoagulants (given once or twice daily) all demonstrated favorable benefit–risk profiles compared with conventional standard therapy for the treatment and secondary prevention of venous thromboembolism and for stroke prevention in patients with nonvalvular atrial fibrillation. In clinical practice, many factors may influence overall clinical outcome...
Source: Clinical and Applied Thrombosis/Hemostasis - August 29, 2016 Category: Hematology Authors: Amin, A., Marrs, J. C. Tags: Review Source Type: research

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
Conclusion: The evidence for each dosing regimen demonstrates that although pharmacology studies are of paramount importance, dose regimens must be subjected to careful empirical validation. Once-daily dosing was shown to be clinically appropriate for most rivaroxaban indications. Furthermore, a "one size fits all" approach to dosing frequency is unlikely to result in a regimen that yields optimal patient outcomes across different indications.
Source: Clinical and Applied Thrombosis/Hemostasis - May 28, 2016 Category: Hematology Authors: Kubitza, D., Berkowitz, S. D., Misselwitz, F. Tags: Reviews Source Type: research

Predictors of Inhospital Mortality in Geriatric Patients Presenting to the Emergency Department With Ischemic Stroke
Conclusion: In evaluating geriatric patients with ischemic stroke, laboratory values including platelet count, creatinine levels, hyperglycemia, and NIHSS scores should be considered to predict inhospital mortality in the ED.
Source: Clinical and Applied Thrombosis/Hemostasis - February 22, 2016 Category: Hematology Authors: Dogan, N. O., Akıncı, E., Gümüs, H., Akıllı, N. B., Aksel, G. Tags: Original Articles Source Type: research

A Seeming Paradox: Ischemic Stroke in the Context of Idiopathic Thrombocytopenic Purpura
Nowadays, we have a relatively sophisticated standard approach to a patient with acute ischemic stroke, including the sequence of diagnostic methods and treatment modalities. In practice, however, we are occasionally confronted with a patient whose medical history or comorbidities force us to make a decision without the support of guidelines. One such situation is the occurrence of acute ischemic stroke in a patient with known idiopathic thrombocytopenic purpura, where a tendency to use thrombolysis, anticoagulants, or antiplatelet agents collides with the fear of life-threatening bleeding. In this review, we try to outlin...
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2016 Category: Hematology Authors: Mihalov, J., Timarova, G. Tags: Reviews Source Type: research

Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey
Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in t...
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2016 Category: Hematology Authors: Aslan, O., Yaylali, Y. T., Yildirim, S., Yurtdas, M., Senol, H., Ugur-Yildiz, M., Ozdemir, M. Tags: Original Articles Source Type: research

Platelet Reactivity in Patients With Stroke and Hyperlipidemia, GPIb{alpha} Assessment
The aim of this study was to assess platelet reactivity in patients after ischemic stroke and to investigate the influence of hyperlipidemia (HL) on platelet activity markers. A total of 41 patients after ischemic stroke were divided into the following 2 groups: patients with HL and patients with normolipidemia. Expression of CD42b on resting, thrombin-activated blood platelets, and fibrinogen level was assessed. The CD42b-positive platelets were analyzed using the flow cytometer, anti-CD61, and anti-CD42b monoclonal antibodies. The results confirmed increased platelet reactivity to thrombin in all patients after ischemic ...
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2016 Category: Hematology Authors: Pawelczyk, M., Chmielewski, H., Kaczorowska, B., Przybyła, M., Baj, Z. Tags: Original Articles Source Type: research

Flow Augmentation in Acute Ischemic Stroke
There is an urgent need for additional therapeutic options for acute ischemic stroke considering the major pitfalls of the options available. Herein, we briefly review the role of cerebral blood flow, collaterals, vasoreactivity, and reperfusion injury in acute ischemic stroke. Then, we reviewed pharmacological and interventional measures such as volume expansion and induced hypertension, intra-aortic balloon counterpulsation, partial aortic occlusion, extracranial–intracranial carotid bypass surgery, sphenopalatine ganglion stimulation, and transcranial laser therapy with regard to their effects on flow augmentation...
Source: Clinical and Applied Thrombosis/Hemostasis - December 9, 2015 Category: Hematology Authors: Yadollahikhales, G., Borhani-Haghighi, A., Torabi-Nami, M., Edgell, R., Cruz-Flores, S. Tags: Original Articles Source Type: research

Baseline SYNTAX Score and Long-Term Outcome in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Conclusion: The SXscore is an independent predictor of both in-hospital and long-term mortality and MACE in patients with acute STEMI undergoing primary PCI.
Source: Clinical and Applied Thrombosis/Hemostasis - October 5, 2015 Category: Hematology Authors: Akgun, T., Oduncu, V., Bitigen, A., Karabay, C. Y., Erkol, A., Kocabay, G., Ozveren, O., Yildiz, A., Cimen, A. O., Kirma, C. Tags: Original Articles Source Type: research

Factoring in Factor VIII With Acute Ischemic Stroke
There is growing research interest into the etiologies of cryptogenic stroke, in particular as it relates to hypercoagulable states. An elevation in serum levels of the procoagulant factor VIII is recognized as one such culprit of occult cerebral infarctions. It is the objective of the present review to summarize the molecular role of factor VIII in thrombogenesis and its clinical use in the diagnosis and prognosis of acute ischemic stroke. We also discuss the utility of screening for serum factor VIII levels among patients at risk for, or those who have experienced, ischemic stroke.
Source: Clinical and Applied Thrombosis/Hemostasis - September 2, 2015 Category: Hematology Authors: Siegler, J. E., Samai, A., Albright, K. C., Boehme, A. K., Martin-Schild, S. Tags: Review Source Type: research

Clopidogrel Plus Aspirin Prevents Early Neurologic Deterioration and Improves 6-Month Outcome in Patients With Acute Large Artery Atherosclerosis Stroke
Conclusion: Clopidogrel plus aspirin is superior to aspirin alone for reducing END and RIS within 30 days and improves outcomes in certain subgroups at 6 months.
Source: Clinical and Applied Thrombosis/Hemostasis - May 26, 2015 Category: Hematology Authors: Wang, C., Yi, X., Zhang, B., Liao, D., Lin, J., Chi, L. Tags: Original Articles Source Type: research

Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial
Conclusions: Based on AVERROES trial results, among patients with AF unsuitable for warfarin therapy, apixaban use was estimated to be associated with a mean medical cost avoidance of US$735 in a patient-year relative to aspirin. The primary driver was the significant reduction in ischemic stroke rate. The medical cost reduction associated with apixaban use was consistent in sensitivity analyses.
Source: Clinical and Applied Thrombosis/Hemostasis - February 27, 2015 Category: Hematology Authors: Amin, A., Deitelzweig, S., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., Graham, J. Tags: Original Articles Source Type: research

Red Blood Cell Distribution Width in Patients With Cryptogenic Stroke
Conclusion: The RDW >14% increased the risk of CS by 2.5-fold, irrespectively of anemia, inflammation, and lipidic profile.
Source: Clinical and Applied Thrombosis/Hemostasis - February 27, 2015 Category: Hematology Authors: Vaya, A., Hernandez, V., Rivera, L., Hernandez, J. L., Lago, A., Espana, F., Bautista, D. Tags: Original Articles Source Type: research

Predictors of Anticoagulant Treatment in Patients With Nonvalvular Atrial Fibrillation: Results From Atrial Fibrillation in Turkey: Epidemiologic Registry
In this study, we demonstrated that stroke history, persistent/permanent AF, hypertension, DM, and left atrial diameter were positive predictors, whereas advanced age and heart failure were negative predictors of oral anticoagulant use in patients with nonvalvular AF.
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2015 Category: Hematology Authors: Kaya, H., Ertaş, F., Koroğlu, B., Vatan, B., Cağlıyan, C. E., Gedik, S., Yeter, E., Aydin, M., Akil, M. A., Soydinc, M. S., Ozhan, H., Ulgen, M. S., for the AFTER Investigators Tags: Original Articles Source Type: research

Relationship Between Red Cell Distribution Width and Stroke in Patients With Stable Chronic Heart Failure: A Propensity Score Matching Analysis
Conclusion: In conclusion, this study demonstrated that RDW may be important hematological indices for stroke in patients with HF using propensity score analysis.
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2015 Category: Hematology Authors: Kaya, A., Isik, T., Kaya, Y., Enginyurt, O., Gunaydin, Z. Y., Iscanli, M. D., Kurt, M., Tanboga, I. H. Tags: Original Articles Source Type: research